Table 4.
Kinetic release properties of the developed formulations (1n–11n and 1t–11t) and Lasix®.
| Formulations | t20% ± SD b | t50% ± SD b | t90% ± SD b | D.E.% a ± SD b |
|---|---|---|---|---|
| 1t | 169.7 ± 2.5 | 245.7 ± 1.2 | 336.0 ± 2.6 | 49.6 ± 4.0 |
| 2t | 199.7 ± 0.9 | 384.0 ± 1.7 | - | 26.6 ± 0.1 |
| 3t | 144.0 ± 0.8 | 178.7 ± 0.6 | 269.8 ± 1.3 | 60.3 ± 3.8 |
| 4t | 5.7 ± 0.5 | 15.0 ± 0.6 | 27.3 ± 1.1 | 93.8 ± 0.6 |
| 5t | 39.0 ± 0.8 | 83.3 ± 1.5 | 163.3 ± 1.5 | 81.0 ± 2.3 |
| 6t | 31.0 ± 1.6 | 94.7 ± 1.2 | 247.7 ± 2.1 | 76.6 ± 2.5 |
| 7t | 27.3 ± 0.5 | 75.0 ± 1.0 | 159.0 ± 1.7 | 82.4 ± 1.8 |
| 8t | 153.0 ± 0.8 | 211.3 ± 0.6 | 289.0 ± 1.7 | 55.6 ± 0.6 |
| 9t | 126.3 ± 1.2 | 200.3 ± 1.5 | 404.0 ± 2.6 | 59.9 ± 2.4 |
| 10t | 141.7 ± 0.9 | 219.0 ± 1.7 | 438.0 ± 1.00 | 47.9 ± 0.4 |
| 11t | 104.0 ± 1.4 | 156.7 ± 0.6 | 262.7 ± 0.6 | 66.8 ± 2.9 |
| 1n | 167.3 ± 1.7 | 240.3 ± 2.5 | 368.2 ± 1.8 | 51.2 ± 3.9 |
| 2n | 162.3 ± 2.1 | 281.7 ± 2.1 | 380.7 ± 1.5 | 43.4 ± 0.6 |
| 3n | 140.7 ± 0.5 | 171.3 ± 2.3 | 232.0 ± 2.0 | 63.2 ± 1.4 |
| 4n | 6.3 ± 1.2 | 15.0 ± 1.0 | 27.7 ± 2.5 | 93.8 ± 0.6 |
| 5n | 13.3 ± 2.1 | 39.3 ± 0.6 | 103.7 ± 1.5 | 89.0 ± 3.0 |
| 6n | 21.0 ± 2.4 | 59.3 ± 1.2 | 180.7 ± 1.2 | 81.9 ± 1.4 |
| 7n | 12.7 ± 0.5 | 33.3 ± 3.1 | 95.8 ± 2.8 | 89.6 ± 1.1 |
| 8n | 154.0 ± 0.8 | 224.7 ± 3.5 | 343.3 ± 1.2 | 51.6 ± 0.8 |
| 9n | 36.7 ± 0.9 | 154.7 ± 1.5 | 286.3 ± 2.1 | 67.1 ± 1.7 |
| 10n | 52.0 ± 0.8 | 191.7 ± 2.1 | 424.7 ± 2.5 | 59.0 ± 0.9 |
| 11n | 24.7 ± 1.2 | 121.0 ± 3.6 | 236.2 ± 1.8 | 74.8 ± 2.4 |
| Lasix | 16.0 ± 0.0 | 126.0 ± 0.0 | 169.3 ± 0.6 | 79.4 ± 0.1 |
a D.E., dissolution efficiency; b ± SD, standard deviation.